NCT04615468 - A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2022

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG

TQ-B3525

TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

Trial Locations (2)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai